COVID Advisor

Early treatment is critical and the most important factor in managing this disease. COVID-19 is a clinical diagnosis; a confirmed antigen or PCR test is not required. Treatment should be initiated immediately after the onset of flu-like symptoms. The multiple therapies and drugs in this protocol have different mechanisms of action and work synergistically during various phases of the disease. Update:   XBB.1.16 ‘Arcturus’ Is New Covid-19 Variant Under Monitoring By The WHO About I-CARE Protocol The information in this document is our recommended approach to COVID-19 based on the best (and most recent) literature. It is provided as guidance to healthcare providers worldwide on the early treatment of COVID-19. Patients should always consult with their provider before starting any medical treatment. New medications may be added and/or changes made to doses of existing medications as further evidence emerges. Please be sure you are using the latest version of this protocol. Update: T

As rates of infection with influenza and RSV rose in fall/winter 2022, FLCCC adapted the I-PREVENT protocol to include prevention against these viruses. The interventions recommended are likely to reduce the risk and severity of infection with COVID-19, influenza, and RSV infections as well as the common cold. It should be noted that the medications included in the I-PREVENT protocol are inexpensive, safe, and widely available. This protocol includes a section for pre-exposure (long-term) as well as a post-exposure (acute, short-term). About this Protocol The information in this document is our recommended approach to COVID-19 based on the best (and most recent) literature. It is provided as guidance to healthcare providers worldwide on the early treatment of COVID-19. Patients should always consult with their provider before starting any medical treatment. New medications may be added and/or changes made to doses of existing medications as further evidence emerges. Ple

Secondary bacterial infection of the lung (pneumonia) was extremely common in patients with COVID-19, affecting almost half the patients who required support from mechanical ventilation. By applying machine learning to medical record data, scientists at Northwestern University Feinberg School of Medicine found that secondary bacterial pneumonia that does not resolve was a key driver of death in patients with COVID-19. It may even exceed death rates from the viral infection itself. The scientists also found evidence that COVID-19 does not cause a " cytokine storm ," so often believed to cause death. The study was recently published in the  Journal of Clinical Investigation . "Our study highlights the importance of preventing, looking for and aggressively treating secondary  bacterial pneumonia  in  critically ill patients  with severe pneumonia, including those with COVID-19," said senior author Dr. Benjamin Singer, an associate professor of medicine at Northwestern

One   in 10 people infected with the coronavirus during the Omicron era suffered from long COVID, according to preliminary data from a new study — indicating   the syndrome remains a notable threat even in the pandemic’s post-emergency phase. The initial finding, published May 25 in the  Journal of the American Medical Assn. , was based on 2,231 patients who had their first coronavirus infection on or after Dec. 1, 2021, when the Omicron strain started  to dominate the nation . Of them, data indicate that 224 patients, or 10%, were classified as having long COVID six months after their acute infection. The categorization was made after scientists developed their own data-based definition of the syndrome, based on a number of symptoms that were more likely to be seen in patients with a prior coronavirus infection. The effort, scientists said, was an important step toward better defining long COVID, which can be hard to pinpoint because it can’t be easily diagnosed or tested for — unlike

Due to mandated vaccinations in his workplace, Mitchell McConachy, age 25, reluctantly took the jab in 2021. Since then, he has been worrying about adverse events. In 2022, McConachy learned about COVID-19 vaccine adverse events from doctors online and realized his bouts of chest pain and throbbing in his head and wrists might have been attributed to the mRNA shots. He became increasingly concerned that these symptoms might precipitate something direr. McConachy’s experience echoes one of many vaccinated people who are now concerned about potential vaccine risks. Some people didn’t experience any symptoms, but still worry that misfortune will fall on their heads someday in the future. The Rasmussen Reports poll of 1,000 people in December 2022 showed that  57 percent of Americans  are somewhat or very concerned about major vaccine adverse effects. Yet there are options besides concern and worry. Doctors who are treating people who have likely experienced vaccine side effects said that